PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Desloratadine - Allergic rhinitis

PAD Profile : Desloratadine - Allergic rhinitis

Keywords :
Hay fever, hayfever, antihistamines, allergy, seasonal allergic rhinitis, pollen allergy, non-sedating antihistamines
Brand Names Include :
NeoClarityn

Traffic Light Status

Status 1 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
Not a 1st-line option. Use cetirizine or loratadine 1st line.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Non Formulary
Formulations :
  • Oral solution
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date
Guidelines (Local)
01 January 2024

Committee Recommendations

Date
Committee Name
Narrative
05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Desloratadine and levocetirizine are not recommended 1st line as there is little evidence that they confer any additional benefit over the more established non-sedating antihistamines and are more costly - see local guidelines below

Cetirizine or loratadine are the 1st line non-sedating antihistamines

Desloratadine liquid is non-formulary

 

Associated BNF Codes

03. Respiratory System
03.04.01. Antihistamines
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More